{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:13:55Z","timestamp":1791090835348,"version":"4.1.0"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Cholesterol is a lipid of widespread physiologic and pathologic importance, whose homeostasis is tightly regulated through multiple mechanisms, including transport via low-density lipoprotein. Elevated serum low-density lipoprotein strongly correlates with the development of atherosclerotic cardiovascular disease. Cholestatic liver diseases, such as primary biliary cholangitis (PBC), are associated with impaired cholesterol homeostasis. The pathophysiology of hypercholesterolemia of PBC involves defective hepatocyte cholesterol clearance, downregulation of bile synthesis, and increased cholesterogenesis. Lipoprotein X is a highly specific biomarker for cholestasis and, in rare cases, contributes to serum total cholesterol levels &gt;1000\u2009mg\/dL. The extent of hypercholesterolemia in PBC is associated with worse liver-related outcomes; nevertheless, patients with PBC do not have increased risk for atherosclerotic cardiovascular disease. Cardiovascular risk stratification of patients with PBC is most accurately achieved by direct measurement of apolipoprotein B, the protein component of pro-atherosclerotic lipoproteins involved in cholesterol transport. First and second line therapies for the treatment of hypercholesterolemia in cholestatic liver disease are statins and proprotein convertase subtilisin\/kexin type 9 inhibitors, respectively. Apolipoprotein B level should be rechecked periodically to measure therapeutic response.<\/jats:p>","DOI":"10.1097\/crd.0000000000000994","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T13:00:42Z","timestamp":1752238842000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Hypercholesterolemia of Cholestasis"],"prefix":"10.1097","author":[{"given":"Maxwell","family":"Charlat","sequence":"first","affiliation":[{"name":"Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elona","family":"Poltiyelova","sequence":"additional","affiliation":[{"name":"Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Silverman","sequence":"additional","affiliation":[{"name":"Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Lit","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lebovics","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"R2-20250721","first-page":"1129","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults.","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"R3-20250721","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis.","volume":"51","author":"Longo","year":"2002","journal-title":"Gut"},{"key":"R4-20250721","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41580-019-0190-7","article-title":"Mechanisms and regulation of cholesterol homeostasis.","volume":"21","author":"Luo","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R5-20250721","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1194\/jlr.R016675","article-title":"Early steps in steroidogenesis: intracellular cholesterol trafficking.","volume":"52","author":"Miller","year":"2011","journal-title":"J Lipid Res"},{"key":"R6-20250721","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.smj.0000208120.73327.db","article-title":"Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review.","volume":"99","author":"Insull","year":"2006","journal-title":"South Med J"},{"key":"R7-20250721","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.2337\/dc09-S355","article-title":"Bile acids and metabolic regulation.","volume":"32","author":"Staels","year":"2009","journal-title":"Diabetes Care"},{"key":"R8-20250721","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1002\/mco2.476","article-title":"Cholesterol metabolism: physiological regulation and diseases.","volume":"5","author":"Guo","year":"2024","journal-title":"MedComm (2020)"},{"key":"R10-20250721","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1011-1344(01)00171-3","article-title":"Photomedicine: lessons from the Smith\u2013Lemli\u2013Opitz syndrome.","volume":"62","author":"Anstey","year":"2001","journal-title":"J Photochem Photobiol B"},{"key":"R11-20250721","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.addr.2020.05.008","article-title":"Insights into incretin-based therapies for treatment of diabetic dyslipidemia.","volume":"159","author":"Stemmer","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"issue":"suppl_E","key":"R12-20250721","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1016\/S1520-765X(01)90105-1","article-title":"The role of the exogenous pathway in hypercholesterolaemia.","volume":"3","author":"Shepherd","year":"2001","journal-title":"Eur Heart J Suppl"},{"key":"R13-20250721","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"R14-20250721","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3390\/ijms23063346","article-title":"Pathophysiology of atherosclerosis.","volume":"23","author":"Jebari-Benslaiman","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R15-20250721","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3389\/fphys.2018.00526","article-title":"Reverse cholesterol transport: molecular mechanisms and the non-medical approach to enhance HDL cholesterol.","volume":"9","author":"Marques","year":"2018","journal-title":"Front Physiol"},{"key":"R16-20250721","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.204996","article-title":"Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man.","volume":"200","author":"Schwartz","year":"1978","journal-title":"Science"},{"key":"R17-20250721","first-page":"5936","article-title":"Biliary cholesterol secretion: more than a simple ABC.","volume":"16","author":"Dikkers","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R19-20250721","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"R20-20250721","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths.","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"key":"R21-20250721","first-page":"2499","article-title":"Lipid-related markers and cardiovascular disease prediction.","volume":"307","year":"2012","journal-title":"JAMA"},{"key":"R22-20250721","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrcardio.2011.2","article-title":"Pharmacological strategies for lowering LDL cholesterol: statins and beyond.","volume":"8","author":"Brautbar","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"R23-20250721","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials.","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"R24-20250721","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"R25-20250721","doi-asserted-by":"crossref","first-page":"148","DOI":"10.34172\/mejdd.2023.336","article-title":"Evaluation and management of chronic cholestatic liver diseases.","volume":"15","author":"Rini","year":"2023","journal-title":"Middle East J Dig Dis"},{"key":"R27-20250721","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.30148","article-title":"Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients.","volume":"69","author":"Bo\u00eblle","year":"2019","journal-title":"Hepatology"},{"key":"R28-20250721","first-page":"136","article-title":"Liver disease in cystic fibrosis.","volume":"9","author":"Kobelska-Dubiel","year":"2014","journal-title":"Prz Gastroenterol"},{"key":"R29-20250721","doi-asserted-by":"crossref","first-page":"25906","DOI":"10.1038\/srep25906","article-title":"Evolving trends in female to male incidence and male mortality of primary biliary cholangitis.","volume":"6","author":"Lleo","year":"2016","journal-title":"Sci Rep"},{"key":"R30-20250721","doi-asserted-by":"crossref","first-page":"e36039","DOI":"10.1097\/MD.0000000000036039","article-title":"Diagnostic value of anti-mitochondrial antibody in patients with primary biliary cholangitis: a systemic review and meta-analysis.","volume":"102","author":"Xu","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R31-20250721","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary biliary cholangitis.","volume":"404","author":"Tanaka","year":"2024","journal-title":"Lancet"},{"key":"R32-20250721","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacl.2014.05.004","article-title":"Severe hypercholesterolemia and phytosterolemia with extensive xanthomas in primary biliary cirrhosis: Role of biliary excretion on sterol homeostasis.","volume":"8","author":"Baila-Rueda","year":"2014","journal-title":"J Clin Lipidol"},{"key":"R33-20250721","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bbadis.2010.12.021","article-title":"Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease.","volume":"1812","author":"Claudel","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"R34-20250721","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/8755122516687122","article-title":"Obeticholic acid.","volume":"33","author":"Smith","year":"2017","journal-title":"J Pharm Technol"},{"key":"R35-20250721","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with nonalcoholic steatohepatitis.","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J Hepatol"},{"key":"R37-20250721","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1172\/JCI111504","article-title":"Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme a reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat.","volume":"74","author":"Walli","year":"1984","journal-title":"J Clin Invest"},{"key":"R38-20250721","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1042\/bj1570401","article-title":"Investigation of the abnormal low-density lipoproteins occurring in patients with obstructive jaundice.","volume":"157","author":"Kostner","year":"1976","journal-title":"Biochem J"},{"key":"R39-20250721","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1194\/jlr.M400229-JLR200","article-title":"Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation.","volume":"45","author":"Chang","year":"2004","journal-title":"J Lipid Res"},{"key":"R40-20250721","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.numecd.2018.09.006","article-title":"Lipoprotein-X fifty years after its original discovery.","volume":"29","author":"Fellin","year":"2019","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R41-20250721","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.immuni.2016.11.008","article-title":"Cholesterol accumulation in CD11c+ immune cells is a causal and targetable factor in autoimmune disease.","volume":"45","author":"Ito","year":"2016","journal-title":"Immunity"},{"key":"R42-20250721","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1172\/JCI97785","article-title":"Tabas I. Hypercholesterolemia induces T cell expansion in humanized immune mice.","volume":"128","author":"Proto","year":"2018","journal-title":"J Clin Invest"},{"key":"R43-20250721","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cgh.2024.01.039","article-title":"Hypercholesterolemia is associated with dysregulation of lipid metabolism and poor prognosis in primary biliary cholangitis.","volume":"22","author":"Zheng","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R44-20250721","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/cdn\/nzac067.045","article-title":"Prevalence of high cholesterol among the adult U.S. population: NHANES 2013\u20132018.","volume":"6","author":"MacDonald","year":"2022","journal-title":"Curr Dev Nutr"},{"key":"R45-20250721","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.1840150518","article-title":"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?","volume":"15","author":"Crippin","year":"1992","journal-title":"Hepatology"},{"key":"R46-20250721","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/liv.12191","article-title":"Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis.","volume":"33","author":"Cash","year":"2013","journal-title":"Liver Int"},{"key":"R48-20250721","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0168-8278(00)80139-7","article-title":"Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management.","volume":"33","author":"Lammert","year":"2000","journal-title":"J Hepatol"},{"key":"R49-20250721","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/aogs.14380","article-title":"Intrahepatic cholestasis of pregnancy and maternal dyslipidemia: a systematic review and meta-analysis.","volume":"101","author":"Zhan","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R50-20250721","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0889-8553(05)70043-1","article-title":"The mechanism of biliary lipid secretion and its defects.","volume":"28","author":"Elferink","year":"1999","journal-title":"Gastroenterol Clin North Am"},{"key":"R51-20250721","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-4-1","article-title":"Progressive familial intrahepatic cholestasis.","volume":"4","author":"Davit-Spraul","year":"2009","journal-title":"Orphanet J Rare Dis"},{"key":"R52-20250721","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.1840360613","article-title":"Liver disease in cystic fibrosis: a prospective study on incidence.","volume":"36","author":"Colombo","year":"2002","journal-title":"Hepatology"},{"key":"R53-20250721","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11894-009-0081-8","article-title":"Cholestatic liver disease in children.","volume":"12","author":"Santos","year":"2010","journal-title":"Curr Gastroenterol Rep"},{"key":"R54-20250721","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaccas.2022.03.009","article-title":"When LDL cholesterol is not LDL cholesterol: LpX, a clinical lesson.","volume":"4","author":"Huygen","year":"2022","journal-title":"JACC Case Rep"},{"key":"R55-20250721","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.hjc.2016.12.009","article-title":"New-onset severe hypercholesterolemia in a patient with cholestatic liver disease. Should we treat the lipids?","volume":"58","author":"Papakonstantinou","year":"2017","journal-title":"Hellenic J Cardiol"},{"key":"R56-20250721","doi-asserted-by":"crossref","first-page":"924","DOI":"10.5604\/16652681.1171785","article-title":"Severe hypercholesterolemia mediated by lipoprotein X in a patient with cholestasis.","volume":"14","author":"Phatlhane","year":"2015","journal-title":"Ann Hepatol"},{"key":"R57-20250721","doi-asserted-by":"crossref","first-page":"969081","DOI":"10.3389\/fped.2022.969081","article-title":"Case report: unusual and extremely severe lipoprotein X-mediated hypercholesterolemia in extrahepatic pediatric cholestasis.","volume":"10","author":"Colantuono","year":"2022","journal-title":"Front Pediatr"},{"key":"R58-20250721","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/hep.510280506","article-title":"Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia.","volume":"28","author":"S\u00f6r\u00f6s","year":"1998","journal-title":"Hepatology"},{"key":"R59-20250721","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000526854","article-title":"Severe hypercholesterolemia mediated by Lipoprotein X in an immunosuppressed patient: a case report.","volume":"30","author":"Sequeira","year":"2022","journal-title":"GE Port J Gastroenterol"},{"key":"R60-20250721","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2017.0263","article-title":"Treatment of severe hypercholesterolemia in a woman with advanced primary sclerosing cholangitis.","volume":"2","author":"Xiao","year":"2017","journal-title":"JAMA Cardiol"},{"key":"R61-20250721","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.","volume":"56","author":"Boonstra","year":"2012","journal-title":"J Hepatol"},{"key":"R62-20250721","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1111\/j.1572-0241.2008.02092.x","article-title":"Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study.","volume":"103","author":"Solaymani-Dodaran","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R63-20250721","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1039\/D2NA00883A","article-title":"Low-density lipoprotein: a versatile nanoscale platform for targeted delivery.","volume":"5","author":"Dai","year":"2023","journal-title":"Nanoscale Adv"},{"key":"R64-20250721","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.172.3982.475","article-title":"Cholestasis: lamellar structure of the abnormal human serum lipoprotein.","volume":"172","author":"Hamilton","year":"1971","journal-title":"Science"},{"key":"R65-20250721","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0022-2275(20)38428-5","article-title":"Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits.","volume":"29","author":"Nordestgaard","year":"1988","journal-title":"J Lipid Res"},{"key":"R66-20250721","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/flgastro-2018-101124","article-title":"Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy.","volume":"10","author":"Wah-Suarez","year":"2019","journal-title":"Frontline Gastroenterol"},{"key":"R67-20250721","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0016-5085(82)80212-6","article-title":"Cholestatic lipoproteins\u2014their pathogenesis end significance.","volume":"83","author":"Sabesin","year":"1982","journal-title":"Gastroenterology"},{"key":"R68-20250721","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R69-20250721","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy.","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"R70-20250721","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1007\/s10620-009-0988-9","article-title":"Statins in primary biliary cirrhosis: are they safe?","volume":"55","author":"Abu Rajab","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R71-20250721","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-2275(20)31668-0","article-title":"Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration.","volume":"42","author":"Del Puppo","year":"2001","journal-title":"J Lipid Res"},{"key":"R72-20250721","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ajg.2010.102","article-title":"The myth of statin-induced hepatotoxicity.","volume":"105","author":"Bader","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R73-20250721","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"R74-20250721","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"R75-20250721","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6904-9-6","article-title":"Effects of simvastatin 40\u2009mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.","volume":"9","author":"Armitage","year":"2009","journal-title":"BMC Clin Pharmacol"},{"key":"R76-20250721","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis.","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R77-20250721","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2014.08.013","article-title":"Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C.","volume":"62","author":"Simon","year":"2015","journal-title":"J Hepatol"},{"key":"R78-20250721","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"R79-20250721","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"An assessment by the statin liver safety task force: 2014 update.","volume":"8","author":"Bays","year":"2014","journal-title":"J Clin Lipidol"},{"key":"R81-20250721","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"key":"R82-20250721","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/liv.13294","article-title":"Old and new treatments for primary biliary cholangitis.","volume":"37","author":"Chascsa","year":"2017","journal-title":"Liver Int"},{"key":"R83-20250721","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1089-3261(03)00135-1","article-title":"Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.","volume":"8","author":"Paumgartner","year":"2004","journal-title":"Clin Liver Dis"},{"key":"R84-20250721","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"R85-20250721","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hep.1840170408","article-title":"Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis.","volume":"17","author":"Poupon","year":"1993","journal-title":"Hepatology"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T19:00:40Z","timestamp":1753124440000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":78,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000994","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}